Pfizer: shares slightly outperform after clinical trial
(CercleFinance.com) - Shares in Pfizer were slightly up on Tuesday after the US drugmaker and Japanese partner Astellas announced positive results from a Phase 3 trial in patients with non-metastatic castration-resistant prostate cancer.
The results showed that the use of Xtandi plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to ADT alone.
For the record, marketing applications based on the results of the study have already been submitted to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Pfizer shares, which belong to the Dow Jones index, are currently up 0,1% at 34.7 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The results showed that the use of Xtandi plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to ADT alone.
For the record, marketing applications based on the results of the study have already been submitted to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Pfizer shares, which belong to the Dow Jones index, are currently up 0,1% at 34.7 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.